Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.71 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 7/20 | 0.51 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8274997 | 0.83 | NFE2L2 (0.66) | NFE2L2HRH3HPGDGRM2LTA4H | |
| SCHEMBL20958147 | 0.83 | NFE2L2 (1.00) | NFE2L2HRH3HPGDGRM2LTA4H | |
| SCHEMBL506275 | 0.83 | PARP10 (0.59) | HPGDGRM2 | |
| SCHEMBL8276935 | 0.81 | NFE2L2 (0.63) | NFE2L2HRH3HPGDGRM2LTA4H | |
| Hydrochloric Acid SCHEMBL7221109 | 0.81 | PARP10 (0.58) | HPGDGRM2 | |
| SCHEMBL14549598 | 0.81 | NFE2L2 (0.96) | NFE2L2HRH3HPGDGRM2LTA4H | |
| SCHEMBL8276090 | 0.81 | NFE2L2 (0.62) | NFE2L2HRH3HPGDGRM2LTA4H | |
| SCHEMBL23163613 | 0.79 | NFE2L2 (0.70) | NFE2L2HRH3HPGDGRM2LTA4H | |
| SCHEMBL35212115 | 0.79 | NFE2L2 (0.70) | NFE2L2HRH3HPGDGRM2 | |
| SCHEMBL30674531 | 0.79 | NFE2L2 (0.70) | NFE2L2HRH3HPGDGRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1720836-B1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | LILLY CO ELI (US) | 2014-04-16 | — | — | EP | disclosed |
| US-8580780-B2 | 6 substituted 2, 3,4,5 tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonist | ELI LILLY AND COMPANY (US) | 2013-11-12 | — | — | US | disclosed |
| EP-2479168-A1 | 6-Substituted 2,3,4,5-Tetrahydro-1H-Benzo [d]Azepines as 5-HT2C Receptor Agonists | ELI LILLY AND COMPANY (US) | 2012-07-25 | — | — | EP | disclosed |
| US-20120028961-A1 | 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist | ELI LILLY AND COMPANY (US) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028961-A1 | 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist | HTR2C, HTR4, HTR1A | NFE2L2 2522/4885HRH3 316/4885HPGD 3744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.